Objective—To identify the most common etiologic diagnosis and any historical, physical, or other diagnostic variables associated with a definitive etiologic diagnosis for chronic nasal discharge in cats.
Design—Retrospective case series.
Animals—75 cats with nasal discharge of ≥ 1 month's duration.
Procedures—Medical records of affected cats were reviewed for information on signalment, clinical signs, duration and type of nasal discharge, results of clinical examination, laboratory findings, and advanced imaging findings.
Results—A specific etiologic diagnosis for nasal discharge was identified in only 36% of cats. Neoplasia (carcinoma or lymphoma) was the most common etiologic diagnosis. Character and location of nasal discharge did not contribute greatly toward a specific etiologic diagnosis. Sneezing and vomiting were the most common concurrent clinical signs. Routine CBC, serum biochemical panel, and urinalysis did not contribute to a specific etiologic diagnosis. An etiologic diagnosis was more likely in older cats and cats that underwent advanced imaging studies and nasal biopsy.
Conclusions and Clinical Relevance—Although advanced diagnostic testing, including imaging studies and biopsy, increases the likelihood of achieving an etiologic diagnosis, the cause of chronic nasal discharge in cats often remains elusive.
Objective—To determine whether platelet clumps
are homogeneously distributed in blood samples, and
whether platelet concentrations (PC) obtained by use
of impedance and buffy coat analysis can be considered
minimum values when platelet clumps are present.
Sample Population—50 blood samples obtained
from 30 dogs.
Procedure—10 blood samples containing platelet
clumps were used and 10 smears were made from
each sample; amount of platelet clumping was graded
for all 100 smears. Blood from each of 20 healthy
dogs was divided between 2 EDTA tubes before and
after platelet clumping was induced by adenosine
diphosphate (ADP). The PC for each ADP-treated and
untreated sample were measured, using impedance
and quantitative buffy coat analyzers.
Results—Platelet clumps were evident in all 100
blood smears, but the amount of clumping varied considerably
within some samples. Using the impedance
analyzer, the PC of ADP-treated samples were significantly
lower and never higher than the PC of untreated
samples. Using the buffy coat analyzer, some ADPtreated
samples had increased PC; however, significant
differences were not detected between treated
and untreated samples.
Conclusions and Clinical Relevance—Platelet
clumping was not homogeneous within blood samples.
When platelet clumps were identified by direct
examination of blood smears, the PC detected by use
of the impedance analyzer could be considered minimum
values. In contrast, the PC detected by use of
the buffy coat analyzer were sometimes increased.
Useful information can be obtained by measuring PC
in blood with platelet clumps; values obtained by use
of impedance can be considered minimums, and values
obtained by use of buffy coat analysis may be
either minimum values or reasonable estimates of
PC. (J Am Vet Med Assoc 2001;219:1552–1556)
Objective—To determine erythrocyte survival time in Greyhounds.
Animals—6 Greyhounds used as blood donors and 3 privately owned non-Greyhound dogs.
Procedures—In vivo biotinylation of erythrocytes was performed by infusion of biotin—Nhydroxysuccinimide into each dog via a jugular vein catheter. Blood samples were collected 12 hours later and then at weekly intervals and were used to determine the percentage of biotin-labeled erythrocytes at each time point. Erythrocytes were washed, incubated with avidin—fluorescein isothiocyanate, and washed again before the percentage of biotinylated erythrocytes was measured by use of flow cytometry. Survival curves for the percentage of biotinylated erythrocytes were generated, and erythrocyte survival time was defined as the x-intercept of a least squares best-fit line for the linear portion of each curve.
Results—The R for survival curves ranged from 0.93 to 0.99 during the first 10 weeks after infusion of erythrocytes. Erythrocyte survival time for the 3 non-Greyhound dogs was 94, 98, and 116 days, respectively, which was consistent with previously reported values. Erythrocyte survival time for the 6 Greyhounds ranged from 83 to 110 days (mean, 93 days; median, 88 days). As determined by use of in vivo biotinylation, erythrocyte survival times in Greyhounds were similar to those determined for non-Greyhound dogs and did not differ significantly from erythrocyte survival times reported previously for non-Greyhound dogs.
Conclusions and Clinical Relevance—Erythrocyte survival time was similar in Greyhounds and non-Greyhound dogs. Greyhounds can be used as erythrocyte donors without concerns about inherently shorter erythrocyte survival time. (Am J Vet Res 2010;71:1033–1038)
Objective—To determine effects of selegiline
hydrochloride, phenylpropanolamine (PPA), or a combination
of both on physiologic and behavioral variables
Animals—40 adult hound-type dogs.
Procedure—Dogs were assigned to 4 groups. One
group received selegiline (1 mg/kg, PO, q 24 h) and
PPA (1.1 mg/kg, PO, q 8 h), a second group received
selegiline alone, a third group received PPA alone, and
a fourth group received neither drug. Dogs were
observed 3 times/d throughout the 30-day study (daily
during the first week, on alternate days during the
next 2 weeks, and again daily during the final week).
Observers recorded rectal temperature, pulse, respiratory
rate, oscillometric blood pressure, and lead-II
ECG and assessed 4 behaviors, using an analogue
scale. Variables were compared among treatment
groups by use of a 2-factor ANOVA with data categorized
into three 10-day treatment periods. A similar
comparison was made among treatment groups with
data categorized by time of observation (morning,
afternoon, or evening) for all study days.
Results—Variables did not differ among groups at
study initiation. Pulse rate was the only variable that
differed significantly among treatment groups during
the study. During the first 10 days of treatment, dogs
receiving PPA had a lower pulse rate than dogs that
did not. Although signs of illness were apparent in a
few dogs, illness did not appear to be related to treatment.
Conclusion and Clinical Relevance—Adverse
effects were not detected after administration of
selegiline, PPA, or a combination of the drugs in
healthy dogs. (Am J Vet Res 2002;63:827–832)
Objective—To compare blood glucose concentrations
obtained using a point-of-care (POC) analyzer, 5 portable
blood glucose meters (PBGM), and a color reagent test
strip with concentrations obtained using a reference
method, and to compare glucose concentrations
obtained using fresh blood samples in the PBGM with
concentrations obtained using blood anticoagulated
with lithium heparin.
Sample Population—110 blood samples from 34
dogs; glucose concentration of the samples ranged
from 41 to 596 mg/dl.
Procedure—Logistic regression was used to compare
blood glucose concentrations obtained with the
various devices with reference method concentrations.
Ease of use was evaluated subjectively.
Percentage of times a clinical decision would have
been altered if results of each of these methods had
been used, rather than results of the reference
method, was calculated.
Results—For 3 of the PBGM, blood glucose concentrations
obtained with fresh blood were not significantly
different from concentrations obtained with
blood samples anticoagulated with lithium heparin.
None of the devices provided results statistically
equivalent to results of the reference method, but the
POC analyzer was more accurate than the others. For
some samples, reliance on results of the PBGM or
the color test strip would have resulted in erroneous
Conclusions and Clinical Relevance—Although
commercially available PBGM and color test strips
provided blood glucose concentrations reasonably
close to those obtained with reference methods,
some devices were more accurate than others. Use
of results from these devices could lead to erroneous
clinical decisions in some cases. ( J Am Vet Med